A substantial body of evidence confirms that the PPAR signaling pathway is critically involved in the pathogenesis and progression of kidney diseases, and PPARγ agonists exhibit beneficial therapeutic effects in diabetic nephropathy and other renal disorders. The gene discussed is PPARG; the disease is diabetic kidney disease.